2025 was a huge year for diabetes tech from new insulin pumps and apps, longer-wear continuous glucose monitors (CGMs), and more features to make diabetes management more seamless than ever.

Starting off, Abbott had a major year with Libre 3 Plus, expanding pump integrations with Tandem Diabetes, Beta Bionics, and the twiist AID system. At the same time, Abbott issued a Libre 3 sensor recall linked to over 3 million sensors and hundreds of adverse events. Libre brought app updates like Apple Watch support, improved alarms, and new AI driven features with Libre Assist.

Meanwhile, Dexcom introduced its longest lasting CGM yet with the Dexcom G7 15 Day sensor in the U.S. However, ongoing connection issues, community frustration, and the planned discontinuation of the G6 raise questions about trust and long term stability.

Medtronic signaled a reset in 2025, launching the Abbott built Instinct sensor for the 780G system, announcing the MiniMed Go smart pen platform, and confirming plans to spin out Medtronic Diabetes into a standalone MiniMed company.

Other notable shifts included Eversense taking over sales and distribution from Ascensia, Ypsomed restructuring its diabetes business, and Insulet outlining major updates to Omnipod 5 alongside early details on Omnipod 6.

All of these stories are unpacked in our latest podcast episode, where we speak to Kamil Armacky of Nerdabetic for a full year end breakdown of the biggest diabetes tech wins, failures, and what to watch out for in 2026. Listen to the episode above or watch the full conversation below.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.